Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis
27 Septiembre 2022 - 7:47AM
- BentrioTM nasal spray becomes available again in
selected European countries
- Marketing focus is on protection against airborne
allergens
- Partnering discussions for distribution in Europe and
US expected to conclude in Q4 2022
Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to
developing therapeutics that address important unmet medical needs,
today announced that its Bentrio nasal spray will be re-launched in
Europe, initially in Germany, beginning in early October of
2022.
Altamira will market Bentrio for helping to prevent onset and
alleviate allergic symptoms caused by airborne allergens such as
pollen, house dust mites or animal dander. Bentrio’s protective
effects have already been demonstrated clinically with controlled
exposure to house dust mites and grass pollen in allergen challenge
chambers for three and four hours, respectively.
A larger clinical trial comparing Bentrio with a seawater nasal
spray (the “NASAR” study) in Australia under “everyday conditions”
over 14 days was started in 2021 and is ongoing. Interim
safety and efficacy data from the trial helped to support the
successful 510(k) application to the FDA.
Previously, Bentrio had also been marketed in Europe for
protection against airborne viral particles. Altamira considers
that Bentrio’s mode of action is the same, regardless of whether it
provides a barrier against airborne virus or allergen particles, as
was demonstrated in various relevant in vitro assays. However,
certain countries and regions require specifically clinical
performance data to clear Bentrio for such viral indication, and in
particular related to COVID-19. Therefore, the Company recently
stopped marketing Bentrio in the viral infection indication in the
EU and Switzerland.
“We look forward to bringing Bentrio back to the market in
Europe with a labeling specifically for allergic rhinitis,”
commented Thomas Meyer, the Company’s founder, CEO and Chairman.
“We sincerely apologize to pharmacies and consumers for the
interruption in their supplies over the past few weeks, following
the removal from the market of Bentrio with viral infection
co-labelling. Since then, we have advanced our COVAMID trial to
evaluate Bentrio in the treatment of acute COVID-19. Here, we
expect to report clinical data in Q4 2022 which might support a
potential label expansion in those countries and regions requesting
such data in viral infection.”
In parallel with its European re-launch, Altamira is actively
advancing its plans to partner Bentrio for marketing and
distribution in Europe, the US and other key markets, to leverage
established resources in the dynamic OTC consumer health market.
Altamira is confident to conclude its discussions with prospective
partners during Q4 2022.
About Altamira Therapeutics Altamira Therapeutics
(NASDAQ:CYTO) is dedicated to developing therapeutics that address
important unmet medical needs. The Company is currently active in
three areas: the development of RNA therapeutics for extrahepatic
therapeutic targets (OligoPhore™ / SemaPhore™ platforms;
preclinical), nasal sprays for protection against airborne
allergens and, where approved, viruses (Bentrio™; commercial) or
for the treatment of vertigo (AM-125; post Phase 2), and the
development of therapeutics for intratympanic treatment of tinnitus
or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003,
it is headquartered in Hamilton, Bermuda, with its main operations
in Basel, Switzerland. For more information,
visit: www.altamiratherapeutics.com
Forward-Looking Statements This press release may contain
statements that constitute "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Forward-looking
statements are statements other than historical facts and may
include statements that address future operating, financial or
business performance or Altamira Therapeutics' strategies or
expectations. In some cases, you can identify these statements by
forward-looking words such as "may", "might", "will", "should",
"expects", "plans", "anticipates", "believes", "estimates",
"predicts", "projects", "potential", "outlook" or "continue", or
the negative of these terms or other comparable terminology.
Forward-looking statements are based on management's current
expectations and beliefs and involve significant risks and
uncertainties that could cause actual results, developments and
business decisions to differ materially from those contemplated by
these statements. These risks and uncertainties include, but are
not limited to, the approval and timing of commercialization of
AM-301, Altamira Therapeutics' need for and ability to raise
substantial additional funding to continue the development of its
product candidates, the timing and conduct of clinical trials of
Altamira Therapeutics' product candidates, the clinical utility of
Altamira Therapeutics' product candidates, the timing or likelihood
of regulatory filings and approvals, Altamira Therapeutics'
intellectual property position and Altamira Therapeutics' financial
position, including the impact of any future acquisitions,
dispositions, partnerships, license transactions or changes to
Altamira Therapeutics' capital structure, including future
securities offerings. These risks and uncertainties also include,
but are not limited to, those described under the caption "Risk
Factors" in Altamira Therapeutics' Annual Report on Form 20-F for
the year ended December 31, 2021, and in Altamira Therapeutics'
other filings with the SEC, which are available free of charge on
the Securities Exchange Commission's website
at: www.sec.gov . Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those indicated.
All forward-looking statements and all subsequent written and oral
forward-looking statements attributable to Altamira Therapeutics or
to persons acting on behalf of Altamira Therapeutics are expressly
qualified in their entirety by reference to these risks and
uncertainties. You should not place undue reliance on
forward-looking statements. Forward-looking statements speak only
as of the date they are made, and Altamira Therapeutics does not
undertake any obligation to update them in light of new
information, future developments or otherwise, except as may be
required under applicable law.
Investors@altamiratherapeutics.com
800-460-0183
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Altamira Therapeutics (NASDAQ:CYTO)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
